中枢脱髄性疾患

出版社： 中外医学社
著者：
発行日： 2018-02-10
分野： 臨床医学：内科  >  脳神経科学/神経内科学
ISBN： 9784498328006
電子書籍版： 2018-02-10 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

7,480 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

7,480 円(税込)

購入する

商品紹介

神経内科のエキスパートをめざす医師のための新シリーズの、中枢脱髄性疾患編。中枢脱髄性疾患の第一人者が,診療のエッセンスをQ&A形式で易しく解説するほか,エキスパートの診療のエッセンスを学べるコラム「pearls」，各章の最後には症例を交え解説する「Case approach」など充実の内容で,基礎から応用まで，診療の中で誰もが遭遇する疑問に，明快に回答します．

目次

  • I　脱髄性疾患総論
    　1　中枢脱髄性疾患にはどのようなものがありますか
    　2　‌中枢脱髄性疾患の疫学について教えてください（日本人の動向も含む）

    II　疾患概念と臨床症状
    　1　MSはどのような病気か教えてください
    　2　CISとRISについて教えてください
    　3　NMOはどのような病気か教えてください
    　4　‌ADEMはどのような病気か教えてください，再発性のこともありますか
    　5　‌Baló病とtumefactive MSはどのような病気か教えてください
    　6　アトピー性脊髄炎とはどのような病気か教えてください
    　7　CCPDとはどのような病気か教えてください
    　8　小児MSはどのような特徴がありますか
    case approach　MOG抗体陽性脱髄疾患

    III　機序
    　1　MSとNMOの病理像について教えてください
    　2　MSとNMOの遺伝的リスクについて教えてください
    　3　MSとNMOの環境因子について教えてください
    　4　MSの発症機序について教えてください
    　5　MSの動物モデルについて教えてください
    　6　NMOの発症機序について教えてください
    　7　NMOの動物モデルについて教えてください

    IV　検査
    　1　MSやNMOが疑われる患者に必要な検査の手順を教えてください
    　2　MSのMRIの取り方と特徴的な所見について教えてください
    　3　NMOを示唆するMRI所見について教えてください
    　4　中枢脱髄性疾患が疑われる患者ではどのような血液検査をしますか
    　5　脱髄性疾患の髄液所見について教えてください
    　6　‌脱髄性疾患の臨床神経生理検査の種類とその所見について教えてください
    　7　脱髄性疾患の高次脳機能検査・神経心理検査について教えてください
    　8　脱髄性疾患の眼科的検査について教えてください
    case approach　NMOの脊髄病巣

    V　診断
    　1　‌MSはどのように診断しますか，診断ガイドラインにはどのようなものがあり，
    　　　どう利用すればいいでしょうか
    　2　‌NMOはどのように診断しますか，診断ガイドラインはどのようなものがあり，
    　　　どう利用すればよいでしょうか
    　3　MSとNMOで鑑別すべき疾患について教えてください
    　4　‌MSとNMOの視神経炎で鑑別すべき眼疾患にはどんなものがありますか
    　5　ADEMやアトピー性脊髄炎はどのように診断しますか
    　6　小児脱髄性疾患の診断基準について教えてください
    case approach　脳脊髄根末梢神経炎

    VI　急性期治療
    　1　MSの急性期はどのように治療すればいいでしょうか
    　2　NMOの急性期はどのように治療すればいいでしょうか
    　3　‌血液浄化療法にはどのようなものがあり，
    　　　MSやNMOではどのように用いたらいいでしょうか
    case approach　Tumefactive MS

    VII　再発・進行防止と予後
    　1　MSの予後予測因子について教えてください
    　2　MSの疾患修飾薬は日本ではどのようなものが使用できますか
    　3　MSの疾患修飾薬の副作用について教えてください
    　4　‌MSの再発防止はいつ始めてどのように治療薬を選択すればいいでしょうか
    　5　‌疾患修飾薬の治療効果やnon—responderはどうやって判定しますか
    　6　Non—responderのescalationはどうしたらいいでしょうか
    　7　‌MSのinduction therapyはどのような場合にどのような薬を使って行いますか
    　8　‌膠原病やその他の自己免疫性疾患を合併したMSの治療はどうするのでしょうか
    　9　小児MSの治療はどうしたらいいでしょうか
    　10　‌PMLの発症はどうやって診断したらいいでしょうか，
    　　　　PMLが疑われる場合の治療はどうしますか
    　11　NMOの再発防止はどうしたらいいでしょうか
    　12　‌MSとNMOで挙児希望や妊娠のために疾患修飾薬を
    　　　　切り替える場合はどうしたらいいでしょうか
    　13　妊娠中にMS／NMOを再発した場合の治療はどうするのでしょうか
    　14　出産後授乳中の疾患修飾薬はどうしたらいいでしょうか

    VIII　対症療法
    　1　MS／NMO患者を悩ませる後遺症にはどのようなものがありますか
    　2　疼痛の治療はどうするのでしょうか
    　3　易疲労感やうつの治療はどうするのでしょうか
    　4　Uhthoff現象の治療はどうするのでしょうか
    　5　‌記憶障害・注意障害などの認知機能障害の治療はどうするのでしょうか
    　6　痙縮の治療はどうするのでしょうか
    　7　‌排尿障害・排便障害（尿失禁・便失禁を含む）の治療はどうするのでしょうか
    　8　性機能障害の治療はどうするのでしょうか
    　9　リハビリテーションや補助装具はどのようにしたらいいでしょうか

    IX　説明と医療福祉資源
    　1　MS／NMOの医療費助成，患者負担について教えてください
    　2　社会福祉制度や就労・就学支援について教えてください
    　3　MS専門医にはどういう場合に診てもらったらいいでしょうか
    　4　患者・家族への説明はどうしたらいいでしょうか

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 脱髄性疾患総論

P.6 掲載の参考文献
(1) 辻 省次, 総編集. アクチュアル脳・神経疾患の臨床 免疫性神経疾患 病態と治療のすべて. 東京:中山書店;2016.
 
(2) 吉良潤一, 総編集. 免疫性神経疾患-基礎・臨床研究の最新知見-. 大阪:日本臨牀社;2015.
 
(3) 田村 晃, 他編. EBMに基づく脳神経疾患の基本治療指針. 第4版. 東京:メジカルビュー社;2016.
 
P.12 掲載の参考文献
(1) Multiple Sclerosis International Federation. Epidemiology of MS. Atlas of MS 2013. Mult. Scler. Int. Fed. London 2013. http://www.msif.org.
 
(2) Osoegawa M, Kira J, Fukazawa T, et al. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese:nationwide survey results over 30 years. Mult Scler. 2009;15:159-73.
PubMed
(3) Flanagan EP, Cabre P, Weinshenker BG, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol. 2016;79:775-83.
PubMed
(4) Houzen H, Niino M, Hirotani M, et al. Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan. J Neurol Sci. 2012;323:117-22.
PubMed
(5) 保前英希, 脇田雅弘, 長井 梓, 他. 北海道十勝地区におけるNMOSDの有病率とその臨床像の検討-2016年同地区MS/NMOSD疫学調査報告-. 神経免疫学. 2016;21:98.
 
(6) 山口 結, 吉良龍太郎, 原 寿郎. 我が国における小児急性散在性脳脊髄炎, 多発性硬化症の現状. 脳と発達. 2016;42:227-9.
 

II 疾患概念と臨床症状

P.23 掲載の参考文献
(1) Multiple Sclerosis International Federation. Epidemiology of MS. In:Atlas of MS 2013. London:Multiple Sclerosis International Federation;2013. p.8-11.
 
(2) Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis:the 2013 revisions. Neurology. 2014;83:278-86.
PubMed
(3) Kuhle J, Disanto G, Dobson R, et al. Conversion from clinically isolated syndrome to multiple sclerosis:a large multicentre study. Mult Scler. 2015;21:1013-24.
PubMed
(4) Bobholz JA, Rao SM. Cognitive dysfunction in multiple sclerosis:a review of recent developments. Curr Opin Neurol. 2003;16:283-8.
PubMed
(5) Kurtzke JF. Rating neurologic impairment in multiple sclerosis:an expanded disability status scale(EDSS). Neurology. 1983;33:1444-52.
PubMed
P.28 掲載の参考文献
(1) Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis:a consensus approach. Mult Scler. 2008;14:1157-74.
PubMed
(2) Kuhle J, Disanto G, Dobson R, et al. Conversion from clinically isolated syndrome to multiple sclerosis:a large multicenter study. Mult Scler. 2015;21:1013-24.
PubMed
(3) Tintore M, Rovira A, Rio J, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology. 2008;70:1079-83.
PubMed
(4) Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis:a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370:389-97.
PubMed
(5) Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis:5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009;8:987-97.
PubMed
(6) Edan G, Kappos L, Montalban X, et al. Long-term impact of interferon beta-1b in patients with CIS:8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry. 2014;85:1183-9.
PubMed
(7) Kappos L, Edan G, Freedman MS, et al. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology. 2016;87:978-87.
PubMed
(8) De Stefano N, Giogio A, Battaglini M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology. 2010;74:1868-76.
 
(9) Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis:2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292-302.
 
(10) Tumani H, Deisenhammer F, Giovannoni G, et al. Revised McDonald criteria:the per-sisting importance of cerebrospinal fluid analysis. Ann Neurol. 2011;70:520.
 
(11) Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis:the radiologically isolated syndrome. Neurology. 2009;72:800-5.
PubMed
(12) McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis:guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121-7.
PubMed
(13) Okuda DT, Siva A, Kantarci O, et al. Radiologically isolated syndrome:5-year risk for an initial clinical event. PLoS One. 2014;9:e90509.
PubMed
(14) Rojas JI, Patrucco L, Miguez J, et al. Brain atrophy in radiologically isolated syndromes. J Neuroimaging. 2015;25:68-71.
PubMed
(15) Brassat D, Lebrun-Frenay C, Club Francophone de la SEP. Treat patients with radiologically isolated syndrome when the MRI brain scan shows dissemination:yes. Mult Scler. 2012;18:1531-2.
 
(16) Bourdette D, Yadav V. Treat patients with radiologically isolated syndrome when the MRI brain scan shows dissemination in time:no. Mult Scler. 2012;18:1529-30.
PubMed
(17) Tornatore C, Philips T, Khan O, et al. Consensus opinion of US neurologists on practice patterns in RIS, CIS, and RRMS. Neurol Clin Pract. 2016;6:1-10.
 
P.38 掲載の参考文献
(1) Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica:distinction from multiple sclerosis. Lancet. 2004;364:2106-12.
 
(2) Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473-7.
 
(3) Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485-9.
 
(4) Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805-15.
PubMed
(5) Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177-89.
PubMed
(6) Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007;130:1194-205.
PubMed
(7) Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica:distinction from multiple sclerosis. Brain. 2007;130:1224-34.
PubMed
(8) Saji E, Arakawa M, Yanagawa K, et al. Cognitive impairment and cortical degeneration in neuromyelitis optica. Ann Neurol. 2013;73:65-76.
PubMed
(9) Hokari M, Yokoseki A, Arakawa M, et al. Clinicopathological features in anterior visual pathway in neuromyelitis optica. Ann Neurol. 2016;79:605-24.
PubMed
(10) Guo Y, Weigand SD, Popescu BF, et al. Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica. Acta Neuropathol. 2017;133:597-612.
PubMed
(11) Yanagawa K, Kawachi I, Toyoshima Y, et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology. 2009;73:1628-37.
PubMed
(12) Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474-81.
PubMed
P.45 掲載の参考文献
(1) Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders:revisions to the 2007 definitions. Mult Scler. 2013;19:1261-7.
 
(2) Torisu H, Kira R, Ishizaki Y, et al. Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture, Japan. Brain Dev. 2010;32:454-62.
PubMed
(3) Yamaguchi Y, Torisu H, Kira R, et al. A nationwide survey of pediatric acquired demyelinating syndromes in Japan. Neurology. 2016;87:2006-15.
PubMed
(4) Menge T, Hemmer B, Nessler S, et al. Acute disseminated encephalomyelitis:an update. Arch Neurol. 2005;62:1673-80.
PubMed
(5) Callen DJ, Shroff Mm, Branson HM, et al. Role of MRI in the differentiation of ADEM from MS in children. Neurology. 2009;72:968-73.
PubMed
(6) Ketelslegers IA, Van Pelt DE, Bryde S, et al. Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort. Mult Scler. 2015;21:1513-20.
 
(7) Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474-81.
PubMed
P.52 掲載の参考文献
(1) Balo J. Encephalitis periaxialis concentrica. Arch Neurol Psychiatr. 1928;19:242-64.
 
(2) Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions:implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707-17.
PubMed
(3) Lucchinetti CF, Gavrilova RH, Metz I, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain. 2008;131:1759-75.
PubMed
(4) Altintas A, Petek B, Isik N, et al. Clinical and radiological characteristics of tumefactive demyelinating lesions:follow-up study. Mult Scler. 2012;18:1448-53.
PubMed
(5) 清水優子. Tumefactive Demyelinating Disease. MS Frontier. 2013;2:45-8.
Medical*Online
(6) Kobayashi M, Shimizu Y, Shibata N, et al. Gadolinium enhancement patterns of tumefactive demyelinating lesions:correlations with brain biopsy findings and pathophysiology. J Neurol. 2014;261:1902-10.
PubMed
(7) Masdeu JC, Drayer BP, Anderson RE, et al. Multiple sclerosis-when and how to image. American College of Radiology. ACR Appropriateness Criteria. Radiology. 2000;215(Suppl):547-62.
 
(8) Cha S, Pierce S, Knopp EA, et al. Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions. AJNR Am J Neuroradiol. 2001;22:1109-16.
PubMed
(9) Given CA 2nd, Stevens BS, Lee C. The MRI appearance of tumefactive demyelinating lesions. AJR Am J Roentgenol. 2004;182:195-9.
PubMed
(10) Schiepers C, Van Hecke P, Vandenberghe R, et al. Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis. Mult Scler. 1997;3:8-17.
PubMed
(11) Visser F, Wattjes MP, Pouwels PJ, et al. Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology. 2012;79:2000-3.
PubMed
(12) Pilz G, Harrer A, Wipfler P, et al. Tumefactive MS lesions under fingolimod:a case report and literature review. Neurology. 2013;81:1654-8.
PubMed
(13) Jander S, Turowski B, Kieseier BC, et al. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler. 2012;18:1650-2.
PubMed
(14) Wang C, Zhang KN, Wu XM, et al. Balo's disease showing benign clinical course and co-existence with multiple sclerosis-like lesions in Chinese. Mult Scler. 2008;14:418-24.
 
(15) Graber JJ, Kister I, Geyer H, et al. Neuromyelitis optica and concentric rings of Balo in the brainstem. Arch Neurol. 2009;66:274-5.
PubMed
(16) Matsuoka T, Suzuki SO, Suenaga T, et al. Reappraisal of aquaporin-4 astrocytopathy in Asian neuromyelitis optica and multiple sclerosis patients. Brain Pathol. 2011;21:516-32.
PubMed
(17) Hardy TA, Beadnall HN, Sutton IJ, et al. Balo's concentric sclerosis and tumefactive demyelination:a shared immunopathogenesis? J Neurol Sci. 2015;348:279-81.
PubMed
P.59 掲載の参考文献
(1) Kira J, Yamasaki K, Kawano Y, et al. Acute myelitis associated with hyper IgEemia and atopic dermatitis. J Neurol Sci. 1997;148:199-203.
 
(2) Osoegawa M, Ochi H, Minohara M, et al. Myelitis with atopic diathesis:a nationwide survey of 79 cases in Japan. J Neurol Sci. 2003;209:5-11.
PubMed
(3) Isobe N, Kira J, Kawamura N, et al. Neural damage associated with atopic diathesis:a nationwide survey in Japan. Neurology. 2009;73:790-7.
PubMed
(4) Isobe N, Kira J, Kawamura N, et al. First diagnostic criteria for atopic myelitis with special reference to discrimination from myelitis-onset multiple sclerosis. J Neurol Sci. 2012;316:30-5.
PubMed
(5) Kikuchi H, Osoegawa M, Ochi H, et al. Spinal cord lesions of myelitis with hyper-IgEemia and mite antigen specific IgE(atopic myelitis)manifest eosinophic inflammation. J Neurol Sci. 2001;183:73-8.
 
(6) Osoegawa M, Ochi H, Kikuchi H, et al. Eosinophilic myelitis associated with atopic diathesis:a combined neuroimaging and hitopathological study. Acta Neuropathol. 2003;105:289-95.
 
(7) Yamasaki R, Fujii T, Wang B, et al. Allergic inflammation leads to neuropathic pain via glial cell activation. J Neurosci. 2016;36:11929-45.
PubMed
(8) Kanamori Y, Isobe N, Yonekawa T, et al. Multimodality evoked potentials for discrimination of atopic myelitis and multiple sclerosis. Clin Exp Neuroimmunol. 2013;4:29-35.
 
P.66 掲載の参考文献
(1) Zee PC, Cohen BA, Walczak T, et al. Peripheral nervous system involvement in multiple sclerosis. Neurology. 1991;41:457-60.
PubMed
(2) Bouchard C, Lacroix C, Plante V, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology. 1999;52:498-503.
PubMed
(3) Adamovic T, Riou EM, Bernard G, et al. Acute combined central and peripheral nervous system demyelination in children. Pediatr Neurol. 2008;39:307-16.
PubMed
(4) Ogata H, Matsuse D, Yamasaki R, et al. A nationwide survey of combined central and peripheral demyelination in Japan. J Neurol Neurosurg Psychiatry. 2016;87:29-36.
PubMed
(5) Zephir H, Stojkovic T, Latour P, et al. Relapsing demyelinating disease affecting both the central and peripheral nervous systems. J Neurol Neurosurg Psychiatry. 2008;79:1032-9.
PubMed
(6) Cortese A, Franciotta D, Alfonsi E, et al. Combined central and peripheral demyelination:Clinical features, diagnostic findings, and treatment. J Neurol Sci. 2016;363:182-7.
PubMed
(7) Shima S, Kawamura N, Ishikawa T, et al. Anti-neutral glycolipid antibodies in encephalomyeloradiculoneuropathy. Neurology. 2014;82:114-8.
PubMed
P.72 掲載の参考文献
(1) Waldman A, Ness J, Pohl D, et al. Pediatric multiple sclerosis:clinical features and outcome. Neurology. 2016;87:S74-81.
PubMed
(2) Yamaguchi Y, Torisu H, Kira R, et al. A nationwide survey of pediatric acquired demyelinating syndromes in Japan. Neurology. 2016;87:2006-15.
PubMed
(3) Benson LA, Healy BC, Gorman MP, et al. Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years. Mult Scler Relat Disord. 2014;3:186-93.
PubMed
(4) Renoux C, Vukusic S, Mikaeloff Y, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007;356:2603-13.
PubMed
(5) Banwell B, Bar-Or A, Arnold DL, et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination:a prospective national cohort study. Lancet Neurol. 2010;10:436-45.
PubMed
(6) Osoegawa M, Kira J, Fukazawa T, et al. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese:nationwide survey results over 30 years. Mult Scler. 2009;15:159-73.
PubMed
P.77 掲載の参考文献
(1) Probstel AK, Dornmair K, Bittner R, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology. 2011;77:580-8.
PubMed
(2) Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies:a comparative study. JAMA Neurol. 2014;71:276-83.
PubMed
(3) Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474-81.
PubMed
(4) Akaishi T, Sato DK, Nakashima I, et al. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies:a comparative study. J Neurol Neurosurg Psychiatry. 2016;87:446-8.
PubMed
(5) Kaneko K, Sato DK, Nakashima I, et al. Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. J Neurol Neurosurg Psychiatry. 2016;87:1257-9.
PubMed
(6) Ogawa R, Nakashima I, Takahashi T, et al. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm. 2017;4:e322.
PubMed

III 機序

P.90 掲載の参考文献
(1) Lassmann H, Raine CS, Antel J, et al. Immunopathology of multiple sclerosis:report on an international meeting held at the institute of neurology of the University of Vienna. J Neuroimmunol. 1998;86:213-7.
 
(2) Lucchinetti C. Multiple sclerosis pathology during early and late disease phases:pathogenic and clinical relevance. In:Zhang J, ed. Immune regulation and immunotherapy in autoimmune disease. New York:Springer;2007. p.214-64.
 
(3) Kuhlmann T, Ludwin S, Prat A, et al. An updated histological classification system for multiple sclerosis lesions. Acta Neuropathol. 2017;133:13-24.
PubMed
(4) Bruck W, Porada P, Poser S, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol. 1995;38:788-96.
PubMed
(5) Frischer JM, Weigand SD, Guo Y, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78:710-21.
PubMed
(6) Bruck W, Lucchinetti C, Lassmann H. The pathology of primary progressive multiple sclerosis. Mult Scler. 2002;8:93-7.
PubMed
(7) Prineas JW, Kwon EE, Cho ES, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol. 2001;50:646-57.
PubMed
(8) Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128:2705-12.
PubMed
(9) Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130:1089-104.
PubMed
(10) Magliozzi R, Howell OW, Reeves C, et al. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol. 2010;68:477-93.
 
(11) Lucchinetti C, Pfeifenbring S, Vlaho S, et al. Heterogeneity of multiple sclerosis lesions:implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707-17.
 
(12) Metz I, Weigand SD, Popescu BF, et al. Pathologic heterogeneity persists in early active multiple sclerosis lesions. Ann Neurol. 2014;75:728-38.
PubMed
(13) Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis:pathology of the newly forming lesion. Ann Neurol. 2004;55:458-68.
PubMed
(14) Matsuoka T, Suzuki SO, Suenaga T, et al. Reappraisal of aquaporin-4 astrocytopathy in Asian neuromyelitis optica and multiple sclerosis patients. Brain Pathol. 2011;21:516-32.
PubMed
(15) Masaki K, Suzuki SO, Matsushita T, et al. Connexin 43 astrocytopathy linked to rapidly progressive multiple sclerosis and neuromyelitis optica. PLoS One. 2013;8:e72919.
PubMed
(16) Vercellino M, Merola A, Piacentino C, et al. Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex:correlation with microglia infiltration, demyelination, and neuronal and synaptic damage. J Neuropathol Exp Neurol. 2007;66:732-39.
PubMed
(17) Lucchinetti C, Popescu BF, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011;365:2188-97.
PubMed
(18) Howell OW, Reeves CA, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. 2011;134:2755-71.
PubMed
(19) Masaki K, Suzuki SO, Matsushita T, et al. Extensive loss of connexins in Balo's disease:evidence for an auto-antibody-independent astrocytopathy via impaired astrocyte-oligodendrocyte/myelin interaction. Acta Neuropathol. 2012;123:887-900.
PubMed
(20) Masaki K. Early disruption of glial communication via connexin gap junction in multiple sclerosis, Balo's disease and neuromyelitis optica. Neuropathology. 2015;35;469-80.
PubMed
(21) Watanabe M, Masaki K, Yamasaki R, et al. Th1 cells downregulate connexin 43 gap junctions in astrocytes via microglial activation. Sci Rep. 2016;6:38387.
PubMed
(22) Boulay AC, Mazeraud A, Cisternino S, et al. Immune quiescence of the brain is set by astroglial connexin 43. J Neurosci. 2015;35:4427-39.
PubMed
(23) Nakahara J, Kanekura K, Nawa M, et al. Abnormal expression of TIP30 and arrested nucleocytplasmic transport within oligodendrocyte precursor cells in multiple sclerosis. J Clin Invest. 2009;119:169-81.
 
(24) Tsai HH, Niu J, Munji R, et al. Oligodendrocyte precursors migrate along vasculature in the developing nervous system. Science. 2016;35:379-84.
 
(25) Maki T, Maeda M, Uemura M, et al. Potential interactions between pericytes and oligodendrocyte precursor cells in perivascular regions of cerebral white matter. Neurosci Lett. 2015;597:164-9.
PubMed
(26) Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002;125:1450-61.
PubMed
(27) Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473-7.
 
(28) Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica:distinction from multiple sclerosis. Brain. 2007;130:1224-34.
PubMed
(29) Hinson SR, Roemer SF, Lucchinetti CF, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med. 2008;205:2473-81.
PubMed
(30) Bruck W, Popescu B, Lucchinetti CF, et al. Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate. Ann Neurol. 2012;72:385-94.
PubMed
(31) Misu T, Hoftberger R, Fujihara K, et al. Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol. 2013;125:815-27.
PubMed
(32) Wrzos C, Winkler A, Metz I, et al. Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions. Acta Neuropathol. 2014;127:523-38.
PubMed
(33) Hayashida S, Masaki K, Yonekawa T, et al. Early and extensive spinal white matter involvement in neuromyelitis optica. Brain Pathol. 2017;27:249-65.
PubMed
(34) Kurosawa K, Misu T, Takai Y, et al. Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody. Acta Neuropathol Commun. 2015;3:82.
PubMed
(35) Saji E, Arakawa M, Yanagawa K, et al. Cognitive impairment and cortical degeneration in neuromyelitis optica. Ann Neurol. 2013;73:65-76.
PubMed
(36) Guo Y, Weigand SD, Popescu BF, et al. Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica. Acta Neuropathol. 2017;133:597-612.
PubMed
P.100 掲載の参考文献
(1) Sadovnick AD, Ebers GC, Dyment DA. et al, The Canadian Collaborative Study Group. Evidence for genetic basis of multiple sclerosis. Lancet. 1996;347:1728-30.
 
(2) Ebers GC, Yee IM, Sadovnick AD, et al;Canadian Collaborative Study Group. Conjugal multiple sclerosis:population-based prevalence and recurrence risks in off-spring. Ann Neurol. 2000;48:927-31.
 
(3) Willer CJ, Dyment DA, Risch NJ, et al, Canadian Collaborative Study Group. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci USA. 2003;100:12877-82.
 
(4) Westerlind H, Ramanujam R, Uvehag D, et al. Modest familial risks for multiple sclerosis:a registry-based study of the population of Sweden. Brain. 2014;137:770-8.
PubMed
(5) Fagnani C, Neale MC, Nistico L, et al. Twin studies in multiple sclerosis:a meta-estimation of heritability and environmentality. Mult Scler. 2015;21:1404-13.
PubMed
(6) Chen G-B, Lee SH, Brion M-JA, et al. Estimation and partitioning of(co)heritability of inflammatory bowel disease from GWAS and immunochip data. Human Molecular Genetics. 2014;23:4710-20.
 
(7) Kuo C-F, Grainge MJ, Valdes AM, et al. Familial aggregation of rheumatoid arthritis and co-aggregation of autoimmune diseases in affected families:a nationwide population-based study. Rheumatology. 2017;56:928-33.
PubMed
(8) Kuo C-F, Grainge MJ, Valdes AM, et al. Familial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families. JAMA Intern Med. 2015;175:1518-26.
PubMed
(9) Haghighi S, Andersen O, Nilsson S, et al. A linkage study in two families with multiple sclerosis and healthy members with oligoclonal CSF immunopathy. Mult Scler. 2006;12:723-30.
 
(10) Willer CJ, Dyment DA, Cherny S, et al. A genome-wide scan in forty large pedigrees with multiple sclerosis. 2007;52:955-62.
PubMed
(11) Dyment DA, Cader MZ, Herrera BM, et al. A genome scan in a single pedigree with a high prevalence of multiple sclerosis. J Neurol Neurosurg Psychiatr. 2008;79:158-62.
 
(12) Sawcer S, Ban M, Maranian M, et al. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet. 2005;77:454-67.
PubMed
(13) Ebers GC, Sadovnick AD, Dyment DA, et al. Parent-of-origin effect in multiple sclerosis:observations in half-siblings. Lancet. 2004;363:1773-4.
PubMed
(14) International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476:214-9.
 
(15) Healy BC, Liguori M, Tran D, et al. HLA B*44:protective effects in MS susceptibility and MRI outcome measures. Neurology. 2010;75:634-40.
PubMed
(16) Patsopoulos NA, Barcellos LF, Hintzen RQ, et al. Fine-mapping the Genetic Association of the Major Histocompatibility Complex in multiple sclerosis:HLA and non-HLA effects. PLoS Genet. 2013;9:e1003926.
PubMed
(17) Marrosu MG, Murru R, Murru MR, et al. Dissection of the HLA association with multiple sclerosis in the founder isolated population of Sardinia. Human Molecular Genetics. 2001;10:2907-16.
PubMed
(18) Yoshimura S, Isobe N, Yonekawa T, et al. Genetic and infectious profiles of Japanese multiple sclerosis patients. PLoS One. 2012;7:e48592.
PubMed
(19) Qiu W, James I, Carroll WM, et al. HLA-DR allele polymorphism and multiple sclerosis in Chinese populations:a meta-analysis. Mult Scler. 2011;17:382-8.
PubMed
(20) Isobe N, Gourraud P-A, Harbo HF, et al. Genetic risk variants in African Americans with multiple sclerosis. Neurology. 2013;81:219-27.
PubMed
(21) Oksenberg JR, Barcellos LF, Cree BAC, et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet. 2004;74:160-7.
 
(22) Imrell K, Greiner E, Hillert J, et al. HLA-DRB115 and cerebrospinal-fluid-specific oligoclonal immunoglobulin G bands lower age at attainment of important disease milestones in multiple sclerosis. J Neuroimmunol. 2009;210:128-30.
PubMed
(23) Goris A, Pauwels I, Gustavsen MW, et al. Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. Brain. 2015;138:632-43.
PubMed
(24) Okuda DT, Srinivasan R, Oksenberg JR, et al. Genotype-phenotype correlations in multiple sclerosis:HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. 2009;132:250-9.
PubMed
(25) Shinoda K, Matsushita T, Nakamura Y, et al. HLA-DRB1*04:05 allele is associated with intracortical lesions on three-dimensional double inversion recovery images in Japanese patients with multiple sclerosis. Mult Scler. 2017. doi:10.1177/1352458517707067.
 
(26) International Multiple Sclerosis Genetics Consortium, Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study.N Engl J Med. 2007;357:851-62.
PubMed
(27) Comabella M, Craig DW, Camina-Tato M, et al. Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. PLoS One. 2008;3:e3490.
PubMed
(28) de Jager PL, Jia X, Wang J, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009;41:776-82.
 
(29) International Multiple Sclerosis Genetics Consortium(IMSGC), Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45:1353-60.
PubMed
(30) International Multiple Sclerosis Genetics Consortium, Patsopoulos N, Baranzini SE, Santaniello A, et al. The Multiple Sclerosis Genomic Map:Role of peripheral immune cells and resident microglia in susceptibility. bioRxiv. 2017. doi:http://dx.doi.org/10.1101/143933
 
(31) Gregory SG, Schmidt S, Seth P, et al. Interleukin 7 receptor alpha chain(IL7R)shows allelic and functional association with multiple sclerosis. Nat Genet. 2007;39:1083-91.
PubMed
(32) Maier LM, Anderson DE, Severson CA, et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol. 2009;182:1541-7.
PubMed
(33) Gregory AP, Dendrou CA, Attfield KE, et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature. 2012;488:508-11.
PubMed
(34) de Jager PL, Baecher-Allan C, Maier LM, et al. The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci USA. 2009;106:5264-9.
PubMed
(35) Didonna A, Isobe N, Caillier SJ, et al. A non-synonymous single-nucleotide polymorphism associated with multiple sclerosis risk affects the EVI5 interactome. Human Molecular Genetics. 2015;24:7151-8.
PubMed
(36) Steri M, Orru V, Idda ML, et al. Overexpression of the cytokine BAFF and autoimmunity risk. N Engl J Med. 2017;376:1615-26.
 
(37) Yoshimura S, Isobe N, Matsushita T, et al. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status. J Neurol Neurosurg Psychiatr. 2013;84:29-34.
 
(38) Wang H, Dai Y, Qiu W, et al. HLA-DPB1 0501 is associated with susceptibility to anti-aquaporin-4 antibodies positive neuromyelitis optica in southern Han Chinese. J Neuroimmunol. 2011;233:181-4.
 
(39) Zephir H, Fajardy I, Outteryck O, et al. Is neuromyelitis optica associated with human leukocyte antigen? Mult Scler. 2009;15:571-9.
PubMed
(40) Brum DG, Barreira AA, Santos dos AC, et al. HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis. Mult Scler. 2010;16:21-9.
 
(41) Deschamps R, Paturel L, Jeannin S, et al. Different HLA class II(DRB1 and DQB1)alleles determine either susceptibility or resistance to NMO and multiple sclerosis among the French Afro-Caribbean population. Mult Scler. 2011;17:24-31.
PubMed
(42) Kim HJ, Park H-Y, Kim E, et al. Common CYP7A1 promoter polymorphism associated with risk of neuromyelitis optica. Neurobiol Dis. 2010;37:349-55.
PubMed
P.108 掲載の参考文献
(1) Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017;13:25-36.
PubMed
(2) Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I:the role of infection. Ann Neurol. 2007;61:288-99.
PubMed
(3) Belbasis L, Bellou V, Evangelou E, et al. Environmental risk factors and multiple sclerosis:an umberella environmental risk factors and multiple sclerosis:an umbrella review of systematic reviews and meta-analysis. Lancet Neurol. 2015;14:263-73.
PubMed
(4) Niino M, Sato S, Fukazawa T, et al. Latitude and HLA-DRB1 alleles independently affect the emergence of cerebrospinal fluid IgG abnormality in multiple sclerosis. Mult Scler. 2015;21:1112-20.
PubMed
P.114 掲載の参考文献
(1) Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2015;23:683-747.
 
(2) Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15:545-8.
PubMed
(3) Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol. 2015;14:406-19.
PubMed
(4) Lassmann H, Bradl M. Multiple sclerosis:experimental models and reality. Acta Neuropathol. 2017;133:223-44.
PubMed
(5) Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lyfe style and environmental risk factors for multiple sclerosis. Nat Rev Immunol. 2017;13:25-36.
 
P.120 掲載の参考文献
(1) Moore GRW, Stadelman-Nessler C. Demyelinating diseases. In:Love S, Budka H, Ironside JW, Perry A, eds. Greenfield's Neuropathology. 9th ed. Boca Raton, FL:CRC Press;2015. p.1297-412.
 
(2) 三宅幸子. 免疫性神経疾患の動物モデル. In:楠 進, 編. 免疫性神経疾患ハンドブック. 東京:南江堂;2013. p.50-7.
 
(3) Didonna A. Preclinical models of multiple sclerosis:advantages and limitations towards better therapies. Curr Med Chem. 2016;23:1442-59.
PubMed
(4) 角田郁生, 尾村誠一, 佐藤文孝, 他. ウイルス感染によって誘導される"軸索型"多発性硬化症動物モデル:インサイド-アウト・モデル. 神経感染症. 2017;22:28-35.
 
(5) Keough MB, Jensen SK, Yong VW. Experimental demyelination and remyelination of murine spinal cord by focal injection of lysolecithin. J Vis Exp. 2015(97). doi:10.3791/52679.
 
P.125 掲載の参考文献
(1) Sato DK, Callegaro D, de Haidar Jorge FM, et al. Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks. Ann Neurol. 2014;76:305-9.
PubMed
(2) Kuroda H, Fujihara K, Takano R, et al. Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J Neuroimmunol. 2013;254:178-82.
PubMed
(3) Uzawa A, Mori M, Sawai S, et al. Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clin Chim Acta. 2013;421:181-3.
PubMed
(4) Chihara N, Aranami T, Oki S, et al. Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica. PLoS One. 2013;8:e83036.
PubMed
(5) Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474-81.
PubMed
P.132 掲載の参考文献
(1) Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica:pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009;66:630-43.
PubMed
(2) Kitic M, Hochmeister S, Wimmer I, et al. Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats. Acta Neuropathol Commun. 2013;1:5.
PubMed
(3) Saadoun S, Waters P, Owens GP, et al. Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun. 2014;2:35.
PubMed
(4) Geis C, Ritter C, Ruschil C, et al. The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in rat passive-transfer model. Exp Neurol. 2015;265:8-21.
PubMed
(5) Kurosawa K, Misu T, Takai Y, et al. Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody. Acta Neuropathol Commun. 2015;3:82.
PubMed

IV 検査

P.138 掲載の参考文献
(1) Kawai M, Shimizu F, Omoto M, et al. Neuromyelitis optica shows hypermetabolism in 18-fluorodeoxyglucose positron emission tomography. Clin Exp Neuroimmunol. 2012;3:85-7.
 
(2) Dobson R, Ramagopalan S, Davis A, et al. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes:a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry. 2013;84:909-14.
 
(3) Nakashima I, Fujihara K, Sato S, et al. Oligoclonal IgG bands in Japanese patients with multiple sclerosis. A comparative study between isoelectric focusing with IgG immunofixation and high-resolution agarose gel electrophoresis. J Neuroimmunol. 2005;159:133-6.
PubMed
(4) Kikuchi S, Fukazawa T, Niino M, et al. HLA-related subpopulations of MS in Japanese with and without oligoclonal IgG bands. Neurology. 2003;60:647-51.
PubMed
(5) 田中正美, 田中惠子. 抗アクアポリン4抗体測定系の検討:cell-based assayとELISAの比較. 神経内科. 2014;81:685-7.
 
(6) Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474-81.
PubMed
(7) Rao SM, Leo GJ, Bernardin L, et al. Cognitive dysfunction in multiple sclerosis. Frequency, patterns, and prediction. Neurology. 1991;41:685-91.
PubMed
(8) Lanz M, Hahn HK, Hildebrandt H. Brain atrophy and cognitive impairment in multiple sclerosis:a review. J Neurol. 2007;254:43-8.
 
(9) Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008;9:453-66.
PubMed
(10) Brownlee WJ, Hardy TA, Fazekas F, et al. Diagnosis of multiple sclerosis:progress and challenges. Lancet. 2017;389:1336-46.
PubMed
P.147 掲載の参考文献
(1) Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis:2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292-302.
 
(2) Rovira A, Wattjes MP, Tintore M, et al. Evidence-based guidelines:MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol. 2015;11:1-12.
 
(3) Nakashima I, Fujihara K, Okita N, et al. Clinical and MRI study of brain stem and cerebellar involvement in Japanese patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 1999;67:153-7.
PubMed
(4) Kearney H, Miszkiel KA, Yiannakas MC, et al. Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis. Mult Scler. 2015;20:910-20.
 
(5) Absinta M, Vuolo L, Rao A, et al. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology. 2015;85:18-28.
PubMed
(6) Wattjes MP, Rovira A, Miller D, et al. Evidence-based guidelines:MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients. Nat Rev Neurol. 2015;11:597-606.
PubMed
(7) Kappos L, De Stefano N, Freedman MS, et al. Inclusion of brain volume loss in a revised measure of "no evidence of disease activity"(NEDA-4)in relapsing-remitting multiple sclerosis. Mult Scler. 2016;22:1297-305.
 
(8) Filippi M, Rocca MA, Ciccarelli O, et al. MRI criteria for the diagnosis of multiple sclerosis:MAGNIMS consensus guidelines. Lancet Neurol. 2016;15:292-303.
PubMed
P.154 掲載の参考文献
(1) Yonezu T, Ito S, Mori M, et al. "Bright spotty lesions" on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis. Mult Scler. 2014;20:331-7.
PubMed
(2) Pekcevik Y, Mitchell CH, Mealy MA, et al. Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging. Mult Scler. 2016;22:302-11.
PubMed
(3) Hokari M, Yokoseki A, Arakawa M, et al. Clinicopathological features in anterior visual pathway in neuromyelitis optica. Ann Neurol. 2016;79:605-24.
PubMed
(4) Akaishi T, Nakashima I, Takeshita T, et al. Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica. J Neuroimmunol. 2016;293:28-33.
PubMed
(5) Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder:an international update. Neurology. 2015;84:1165-73.
PubMed
(6) Matthews LA, Palace JA. The role of imaging in diagnosing neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2014;3:284-93.
PubMed
P.161 掲載の参考文献
(1) Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO:a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012;78:665-71.
PubMed
(2) Sato D, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 positive NMO spectrum disorders. Neurology. 2014;82:474-81.
PubMed
(3) Ogata H, Matsuse D, Yamasaki R, et al. A nationwide survey of combined central and peripheral demyelination in Japan. J Neurol Neurosurg Psychiatry. 2016;87:29-36.
PubMed
(4) Comabella M, Montalban X. Body fluid biomarkers in multiple sclerosis. Lancet Neurol. 2014;13:113-26.
PubMed
(5) Niino M, Sato S, Fukazawa T, et al. Decreased serum vitamin D levels in Japanese patients with multiple sclerosis. J Neuroimmunol. 2015;279:40-5.
PubMed
P.166 掲載の参考文献
(1) Reiber H. Cerebrospinal fluid-physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler. 1998;4:99-107.
PubMed
(2) Stangel M, Fredrikson S, Meinl E, et al. The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol. 2013;9:267-76.
PubMed
(3) Jarius S, Paul F, Franciotta D, et al. Cerebrospinal fuid findings in aquaporin-4 antibody positive neuropmyelitis optica:results from 211 lumbar punctures. J Neurol Sci. 2011;306:82-90.
 
(4) Menge T, Hemmer B, Nessler S, et al. Acute disseminated encephalomyelitis. Arch Neurol. 2005;62:1673-80.
PubMed
P.173 掲載の参考文献
(1) 飛松省三. 誘発電位の利用の仕方. MS Frontier. 2014;3:47-50.
Medical*Online
(2) Gronseth GS, Ashman EJ. Practice parameter:the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis(an evidence-based review):Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54:1720-5.
 
(3) Landi D, Vollaro S, Pellegrino G, et al. Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis. Clin Neurophysiol. 2015;126:165-9.
PubMed
(4) 黒川智美, 吉良潤一, 飛松省三. 臨床研究の進歩 検査・診断法の進歩 電気生理学的診断法. 日本臨牀. 2003;61:1347-54.
 
(5) Andersson T, Siden A. Multimodality evoked potentials and neurological phenomenology in patients with multiple sclerosis and potentially related conditions. Electromyogr Clin Neurophysiol. 1991;31:109-17.
PubMed
(6) Kira J, Tobimatsu S, Goto I, et al. Primary progressive versus relapsing remitting multiple sclerosis in Japanese patients:a combined clinical, magnetic resonance imaging and multimodality evoked potential study. J Neurol Sci. 1993;117:179-85.
PubMed
(7) Giffroy X, Maes N, Albert A, et al. Multimodal evoked potentials for functional quantification and prognosis in multiple sclerosis. BMC Neurol. 2016;16:83.
PubMed
P.177 掲載の参考文献
(1) Benedict RH, Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol. 2011;7:332-42.
PubMed
(2) Niino M, Mifune N, Kohriyama T, et al. Apathy/depression, but not subjective fatigue, is related with cognitive dysfunction in patients with multiple sclerosis. BMC Neurol. 2014;14:3.
 
(3) Langdon DW, Amato MP, Boringa J, et al. Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis(BICAMS). Mult Scler. 2012;18:891-8.
PubMed
(4) Boeschoten RE, Braamse AM, Beekman AT, et al. Prevalence of depression and anxiety in multiple sclerosis:a systematic review and meta-analysis. J Neurol Sci. 2017;372:331-41.
PubMed
(5) Litster B, Fiest KM, Patten SB, et al. Screening tools for anxiety in people with multiple sclerosis:a systematic review. Int J MS Care. 2016;18:273-81.
PubMed
P.182 掲載の参考文献
(1) Hokari M, Yokoseki A, Arakawa M, et al. Clinicopathological features in anterior visual pathway in neuromyelitis optica. Ann Neurol. 2016;79:605-24.
PubMed
(2) Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurol. 2014;13:83-99.
PubMed
(3) Kawachi I. Clinical characteristics of autoimmune optic neuritis. Clin Exp Neuroimmunol. 2017;8(S1):8-16.
 
(4) 江本博文, 清澤源弘, 藤野 貞. 眼科検査の基本事項. In:江本博文, 清澤源弘, 藤野 貞. 神経眼科-臨床のために. 3版. 東京:医学書院;2011. p.37-41.
 
(5) 清水夏繪. 神経眼科・神経耳科学的検査. In:水野美邦. 臨床神経ハンドブック. 5版. 東京:医学書院;2016. p.528-41.
 
(6) Jain N, Bhatti MT. Fingolimod-associated macular edema Incidence, detection, and management. Neurology. 2012;78:672-80.
PubMed
P.188 掲載の参考文献
(1) Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177-89.
PubMed
(2) Hayashida S, Masaki K, Yonekawa T, et al. Early and extensive spinal white matter involvement in neuromyelitis optica. Brain Pathol. 2017;27:249-65.
PubMed
(3) Pekcevik Y, Mitchell CH, Mealy MA, et al. Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging. Mult Scler. 2016;22:302-11.
PubMed
(4) Yonezu T, Ito S, Mori M, et al. "Bright spotty lesions" on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis. Mult Scler. 2014;20:331-7.
PubMed
(5) Flanagan EP, Weinshenker BG, Krecke KN, et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol. 2015;72:81-7.
PubMed
(6) Huh SY, Kim SH, Hyun W, et al. Short segment myelitis as a first manifestation of neuromyelitis optica spectrum disorders. Mult Scler 2017;23:413-9.
 
(7) Asgari N, Skejoe HP, Lennon VA. Evolution of longitudinally extensive transverse myelitis in an aquaporin-4 IgG-positive patients. Neurology. 2013;81:95-6.
 
(8) Jurynczyk M, Weinshenker B, Akman-Demir G, et al. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. J Neurol. 2016;263:140-9.
PubMed

V 診断

P.194 掲載の参考文献
(1) Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis:2010 revision to the McDonald criteria. Ann Neurol. 2011;69:292-302.
 
(2) 日本神経治療学会. ガイドライン・標準的神経治療. "多発性硬化症ガイドライン" "多発性硬化症追記情報2012・2013" "McDonald 診断基準":https://ww.jsnt.gr.jp
 
(3) McDonald WI, Compston A, Eden G, et al. Recommended diagnostic criteria for multiple sclerosis:guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121-7.
 
(4) Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica(Devic's syndrome). Neurology. 2006;66:1485-9.
 
(5) Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474-81.
PubMed
(6) Matsui M. Multiple sclerosis:diagnosis and treatment. In:Kusunoki S, ed. Neuroimmunological disease. Springer;2016. p.105-22.
 
P.202 掲載の参考文献
(1) Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica(Devic's syndrome). Neurology. 1999;53:1107-14.
PubMed
(2) Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473-7.
 
(3) Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485-9.
 
(4) Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177-89.
PubMed
(5) Waters P, Vincent A. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica:current status of the assays. Int MS J. 2008;15:99-105.
PubMed
P.208 掲載の参考文献
(1) 加藤大貴, 市川博雄, 林 大吾, 他. 原発性シェーグレン症候群(SjS)に視神経炎と脳脊髄炎を合併し, 抗アクアポリン4抗体が陽性であった25歳女性例. 臨床神経. 2009;49:576-81
 
(2) Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol. 2014;10:338-47.
PubMed
(3) 菊地弘敏, 廣畑俊成. 神経Behcet病の診療ガイドライン. 炎症と免疫. 2014;22:376-81.
Medical*Online
(4) 久永欣哉. 神経好中球病と認知症. Brain Nerve. 2016;68:353-64.
 
(5) 日本サルコイドーシス/肉下腫性疾患学会, 他. サルコイドーシスの診断基準と診断の手引き-2006. 日呼吸会誌. 2008:46:768-80.
 
P.214 掲載の参考文献
(1) Reindl M, Di Pauli F, Rostasy K, et al. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol. 2013;9:455-61.
PubMed
(2) 中馬秀樹. 現在の非動脈炎性虚血性視神経症のみかた, 考え方. あたらしい眼科. 2016;33:663-9.
Medical*Online
(3) Akashi T, Nakashima I, Takeshita T, et al. Different etiologies and prognosis of optic neuritis in demyelinating disease. J Neuroimmunol. 2016;299:152-7.
 
(4) 抗アクアポリン4抗体陽性視神経炎診療ガイドライン作成委員会. 抗アクアポリン4抗体陽性視神経炎診療ガイドライン. 日眼会誌. 2014;118:446-60.
 
(5) 毛塚 剛. 眼科臨床における視神経炎と視神経症の位置づけ. あたらしい眼科. 2016;33:627-31.
Medical*Online
P.219 掲載の参考文献
(1) Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders:revisions to the 2007 definitions. Mult Scler. 2013;10:1261-7.
 
(2) Isobe N, Kanamori Y, Yonekawa T, et al. First diagnostic criteria for atopic myelitis with special reference to from myelitis-onset multiple sclerosis. J Neurol Sci. 2012;316:30-5.
PubMed
P.224 掲載の参考文献
(1) Pohl D, Alper G, Van Haren K, et al. Acute disseminated encephalomyelitis:Updates on an inflammatory CNS syndrome. Neurology. 2016;87:S38-45.
 
(2) Krupp LB, Banwell B, Tenembaum S, et al. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology. 2007;68:S7-12.
 
(3) Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders:revisions to the 2007 definitions. Mult Scler. 2013;19:1261-7.
 
(4) Sadaka Y, Verhey LH, Shroff MM, et al. 2010 McDonald criteria for diagnosing pediatric multiple sclerosis. Ann Neurol. 2012;72:211-23.
PubMed
P.230 掲載の参考文献
(1) Rubin M, Karpati G, Carpenter S, Combined central and peripheral myelinopathy. Neurolgy. 1987;37:1287-90.
 
(2) Kawamura N, Yamasaki R, Yonekawa T, et al. Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology. 2013;81:714-22.
PubMed
(3) Cortese A, Pevaux JI, Zardini E, et al. Neurofascin-155 as a putative antigen in combined central and peripheral demyelination. Neurol Neuroimmunol Neuroinflamm. 2016;3:e238.
 
(4) Blennow G, Gamstroop I, Rosenberg R, Encephalo-myelo-radiculo-neuropathy. Dev Med Child Neurol. 1968;10:485-90.
PubMed
(5) Shima S, Kawamura N, Ishikawa T, et al. Anti-neutral glycolipid antibodies in encephalomyeloradiculoneuropathy. Neurology. 2014;82:114-8.
PubMed
(6) Iwabuchi K, Masuda H, Kaga N, et al. Properties and functions of lactosylceramide from mouse neutrophils. Glycobiology. 2015;25:655-68.
PubMed
(7) Won JS, Singh AK, Singh I, et al. Lactosylceramide:a lipid second messenger in neuroinflammatory disease. J Neurochem. 2007:103 Suppl 1:180-91.
 
(8) Mayo L, Trauger SA, Blain M, et al. Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. Nat Med. 2014;20:1147-56.
PubMed

VI 急性期治療

P.239 掲載の参考文献
(1) Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev. 2000;(4):CD001331.
 
(2) Kira J-i, Yamasaki R, Yoshimura S, et al. Efficacy of methylprednisolone pulse therapy for acute relapse in Japanese patients with multiple sclerosis and neuromyelitis optica:a multicenter retrospective analysis-1. Whole group analysis. Clin Exp Neuroimmunol. 2013;4:305.
 
(3) Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46:878-86.
 
(4) Le Page E, Veillard D, Laplaud DA, et al. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis(COPOUSEP):a randomised, controlled, double-blind, non-inferiority trial. Lancet. 2015;386:974-81.
PubMed
(5) Sellebjerg F, Frederiksen JL, Nielsen PM, et al. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology. 1998;51:529-34.
 
(6) 日本神経学会/日本神経免疫学会/日本神経治療学会, 監. 「多発性硬化症治療ガイドライン」作成委員会, 編. 多発性硬化症治療ガイドライン2010. 東京:医学書院;2010.
 
(7) The Optic Neuritis Study Group. Visual function 15 years after optic neuritis:a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology. 2008;115:1079-82.
 
P.245 掲載の参考文献
(1) 日本神経学会, 編. 多発性硬化症・視神経脊髄炎診療ガイドライン2017. 東京:医学書院;2017.
 
(2) Kleiter I, Gold R. Present and future therapies in Neuromyelitis optica spectrum disorders. Neurotherapeutics. 2016;13:70-83.
PubMed
(3) Kessler RA, Mealy MA, Levy M. Treatment of neuromyelitis optica spectrum disorder:acute, preventive, and symptomatic. Curr Treat Options Neurol. 2016;18:2.
PubMed
(4) Bonnan M, Cabre P. Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int. 2012;2012:787630.
PubMed
(5) Elsone L, Panicker J, Mutch K, et al. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica:experience in 10 patients. Mult Scler. 2014;20:501-4.
PubMed
P.250 掲載の参考文献
(1) Keegan M, Konig F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet. 2005;366:579-82.
PubMed
(2) Ruprecht K, Klinker E, Dintelmann T, et al. Plasma exchange for severe optic neuritis:treatment of 10 patients. Neurology. 2004;63:1081-3.
PubMed
(3) Watanabe S, Nakashima I, Misu T, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler. 2007;13:128-32.
PubMed
(4) 井口貴子, 王子 聡, 伊崎祥子, 他. LSCLを有しステロイド治療抵抗性MSに対する免疫吸着療法-抗AQP4抗体とIgGサブクラス. 神経免疫学. 2008;16:53.
 
P.254 掲載の参考文献
(1) Hashimoto Y, Shinoda K, Tanaka E, et al. Re-emergence of a tumefactive demyelinating lesion after initiation of fingolimod therapy. J Neurol Sci. 2017;379:167-8.
PubMed
(2) Hardy TA, Chataway J. Tumefactive demyelination:an approach to diagnosis and management. J Neurol Neurosurg Psychiatry. 2013;84:1047-53.
PubMed
(3) Seifert CL, Wegner C, Sprenger T, et al. Favourable response to plasma exchange in tumefactive CNS demyelination with delayed B-cell response. Mult Scler. 2012;18:1045-49.
PubMed
(4) Lucchinetti CF, Gavrilova RH, Metz I, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain. 2008;131:1759-75.
PubMed
(5) Altintas A, Petek B, Isik N, et al. Clinical and radiological characteristics of tumefactive demyelinating lesions:follow-up study. Mult Scler. 2012;18:1448-53.
PubMed
(6) Pilz G, Harrer A, Wipfler P, et al. Tumefactive MS lesions under fingolimod:a case report and literature review. Neurology. 2013;81:1654-8.
PubMed
(7) Hellmann MA, Lev N, Lotan I, et al. Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy. J Neurol Sci. 2014;344:193-7.
 

VII 再発・進行防止と予後

P.260 掲載の参考文献
(1) Degenhardt A, Ramagopalan SV, Scalfari A, et al. Clinical prognostic factors in multiple sclerosis:a natural history review. Nat Rev Neurol. 2009;5:672-82.
PubMed
(2) Sayao AL, Devonshire V, Tremlett H. Longitudinal follow-up of "benign" multiple sclerosis at 20 years. Neurology. 2007;68:496-500.
PubMed
(3) Ramsaransing GS, De Keyser J. Predictive value of clinical characteristics for 'benign' multiple sclerosis. Eur J Neurol. 2007;14:885-9.
PubMed
(4) Sartori A, Abdoli M, Freedman MS. Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study. J Neurol. 2017;264:1068-75.
PubMed
(5) Wallin MT, Page WF, Kurtzke JF. Epidemiology of multiple sclerosis in US veterans. VIII. Long-term survival after onset of multiple sclerosis. Brain. 2000;123(Pt 8):1677-87.
 
(6) Vukusic S, Confavreux C. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci. 2003;206:135-7.
PubMed
(7) Langer-Gould A, Popat RA, Huang SM, et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis:a systematic review. Arch Neurol. 2006;63:1686-91.
PubMed
(8) Amato MP, Ponziani G, Bartolozzi ML, et al. A prospective study on the natural history of multiple sclerosis:clues to the conduct and interpretation of clinical trials. J Neurol Sci. 1999;168:96-106.
 
(9) Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology. 2006;66:172-7.
PubMed
(10) Myhr KM, Riise T, Vedeler C, et al. Disability and prognosis in multiple sclerosis:demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler. 2001;7:59-65.
PubMed
(11) Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain. 2006;129:595-605.
PubMed
(12) Confavreux C, Vukusic S. Natural history of multiple sclerosis:a unifying concept. Brain. 2006;129:606-16.
PubMed
(13) Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med. 1998;339:285-91.
 
(14) Vukusic S, Hutchinson M, Hours M, et al. Pregnancy and multiple sclerosis(the PRIMS study):clinical predictors of post-partum relapse. Brain. 2004;127:1353-60.
PubMed
(15) Pozzilli C, Pugliatti M, Paradig MSG. An overview of pregnancy-related issues in patients with multiple sclerosis. Eur J Neurol. 2015;22(Suppl 2):34-9.
 
(16) Masera S, Cavalla P, Prosperini L, et al. Parity is associated with a longer time to reach irreversible disability milestones in women with multiple sclerosis. Mult Scler. 2015;21:1291-7.
PubMed
(17) Jokubaitis VG, Spelman T, Kalincik T, et al. Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Ann Neurol. 2016;80:89-100.
PubMed
(18) Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions:a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008;131:808-17.
 
(19) Tintore M, Rovira A, Arrambide G, et al. Brainstem lesions in clinically isolated syndromes. Neurology. 2010;75:1933-8.
PubMed
(20) Sombekke MH, Wattjes MP, Balk LJ, et al. Spinal cord lesions in patients with clinically isolated syndrome:a powerful tool in diagnosis and prognosis. Neurology. 2013;80:69-75.
 
(21) Minneboo A, Barkhof F, Polman CH, et al. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol. 2004;61:217-21.
PubMed
(22) Tintore M, Rovira A, Rio J, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015;138:1863-74.
PubMed
P.269 掲載の参考文献
(1) Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis:results of a 2-year prospective randomised multicentre study(INCOMIN). Lancet. 2002;359:1453-60.
PubMed
(2) Limmroth V, Putzki N, Kachuck NJ. The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis:are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination. Ther Adv Neurol Disord. 2011;4:281-96.
PubMed
(3) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43:655-61.
 
(4) Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group(MSCRG). Ann Neurol. 1996;39:285-94.
 
(5) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS(Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis)Study Group. Lancet. 1998;352:1498-504.
 
(6) Saida T, Tashiro K, Itoyama Y, et al. Interferon beta-1b is effective in Japanese RRMS patients:a randomized, multicenter study. Neurology. 2005;64:621-30.
PubMed
(7) 隅野瑠理子. 多発性硬化症治療薬インターフェロンベータ-1a製剤(アボネックス筋注用シリンジ30μg)の薬理学的特性および臨床試験成績. 日薬理誌. 2007;129:209-17.
 
(8) Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet. 1998;352:1491-7.
 
(9) Panitch H, Miller A, Paty D, et al;North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS:results from a 3-year controlled study. Neurology. 2004;63:1788-95.
 
(10) Cohen JA, Cutter GR, Fischer JS, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol. 2001;58:961-7.
 
(11) Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MSSG. Randomized controlled trial of interferon-beta-1a in secondary progressive MS:Clinical results. Neurology. 2001;56:1496-504.
 
(12) Molyneux PD, Barker GJ, Barkhof F, et al. Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. Neurology. 2001;57:2191-7.
 
(13) Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS:a combined analysis of the two trials. Neurology. 2004;63:1779-87.
 
(14) Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242-9.
 
(15) Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343:898-904.
 
(16) Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis:a randomised study. Lancet. 2001;357:1576-82.
PubMed
(17) Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis:a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370:389-97.
PubMed
(18) Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis:5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009;8:987-97.
PubMed
(19) Edan G, Kappos L, Montalban X, et al. Long-term impact of interferon beta-1b in patients with CIS:8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry. 2014;85:1183-9.
PubMed
(20) Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006;66:678-84.
PubMed
(21) Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis:results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45:1268-76.
 
(22) Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol. 2001;49:290-7.
 
(23) Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome(Pre-CISe study):a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1503-11.
 
(24) Comi G, Martinelli V, Rodegher M, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler. 2013;19:1074-83.
 
(25) Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387-401.
 
(26) Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402-15.
 
(27) Saida T, Kikuchi S, Itoyama Y, et al. A randomized, controlled trial of fingolimod(FTY720)in Japanese patients with multiple sclerosis. Mult Scler. 2012;18:1269-77.
PubMed
(28) Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098-107.
PubMed
(29) Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087-97.
PubMed
(30) Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899-910.
PubMed
(31) Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911-23.
PubMed
(32) Saida T, Kira JI, Kishida S, et al. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients:a double-blind, randomized controlled trial and open-label pharmacokinetic study. Mult Scler Relat Disord. 2017;11:25-31.
PubMed
(33) Ontaneda D, Thompson AJ, Fox RJ, et al. Progressive multiple sclerosis:prospects for disease therapy, repair, and restoration of function. Lancet. 2017;389:1357-66.
PubMed
P.279 掲載の参考文献
(1) 日本神経学会, 日本神経免疫学会, 日本神経治療学会, 監修. 多発性硬化症治療ガイドライン2010. https://www.neurology-jp.org/guidelinem/koukashou.html
 
(2) Bachelet D, Hassler S, Mbogning C, et al. Occurrence of anti-drug antibodies against interferon-beta and natalizumab in multiple sclerosis:a collaborative cohort analysis. PLoS One. 2016;11:e0162752
PubMed
(3) 端 祐一郎, 近藤誉之. 多発性硬化症の治療 再発・進行防止の治療 フィンゴリモド. 日本臨牀. 2015;73(増刊号7):205-11.
 
(4) Kira J, Itoyama Y, Kikuchi S, et al. Fingolimod(FTY720)therapy in Japanese patients with relapsing multiple sclerosis over 12 months:results of a phase 2 observational extension. BMC Neurology. 2014;14:21.
PubMed
(5) Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402-15.
 
(6) Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098-107.
PubMed
(7) Xu Z, Zhang F, Sun F, et al. Dimethyl fumarate for multiple sclerosis. Cochrane Database Syst Rev. 2015:(4):CD011076.
PubMed
(8) Phillips JT, Selmaj K, Gold R, et al. Clinical significance of gastrointestinal and flushing events in patients with multiple sclerosis treated with delayed-release dimethyl fumarate. Int J MS Care. 2015;17:236-43.
PubMed
(9) Amend KL, Turnbull B, Foskett N, et al. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology. 2010;75:1326-32.
PubMed
P.286 掲載の参考文献
(1) Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I:natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005;4:281-8.
PubMed
(2) Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis:the radiologically isolated syndrome. Neurology. 2009;72:800-5.
PubMed
(3) Okuda DT, Mowry EM, Cree BA, et al. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology. 2011;76:686-92.
PubMed
(4) Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343:898-904.
 
(5) Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242-9.
 
(6) Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome(Pre-CISe study):a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1503-11.
 
(7) Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis:a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370:389-97.
PubMed
(8) Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis:5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009;8:987-97.
PubMed
(9) Edan G, Kappos L, Montalban X, et al. Long-term impact of interferon beta-1b in patients with CIS:8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry. 2014;85:1183-9.
PubMed
(10) Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006;66:678-84.
PubMed
(11) Comi G, Martinelli V, Rodegher M, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler. 2013;19:1074-83.
 
(12) Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology. 2006;67:944-53.
 
(13) Ebers GC, Traboulsee A, Li D, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010;81:907-12.
 
(14) Goodin DS, Jones J, Li D, et al. Establishing long-term efficacy in chronic disease:use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One. 2011;6:e22444.
 
(15) Goodin DS, Reder AT, Ebers GC, et al. Survival in MS:a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. Neurology. 2012;78:1315-22.
 
(16) Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet. 1998;352:1491-7.
 
(17) Panitch H, Miller A, Paty D, et al;North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS:results from a 3-year controlled study. Neurology. 2004;63:1788-95.
 
(18) Cohen JA, Cutter GR, Fischer JS, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol. 2001;58:961-7.
 
(19) Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MSSG. Randomized controlled trial of interferon-beta-1a in secondary progressive MS:Clinical results. Neurology. 2001;56:1496-504.
 
(20) Molyneux PD, Barker GJ, Barkhof F, et al. Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. Neurology. 2001;57:2191-7.
 
(21) Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain. 2000;123(Pt 11):2256-63.
 
(22) Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS:a combined analysis of the two trials. Neurology. 2004;63:1779-87.
 
(23) Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS:an exploratory, randomized, controlled trial. Neurology. 2003;60:44-51.
 
(24) Montalban X. Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis. Mult Scler. 2004;10:S62.
 
(25) Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002;59:679-87.
 
(26) Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870-80.
 
(27) Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76:802-12.
 
(28) Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med. 2013;368:1657-8.
 
(29) van Oosten BW, Killestein J, Wattjes MP. Case reports of PML in patients treated for psoriasis. N Engl J Med. 2013;369:1081-2.
 
(30) Mrowietz U, Reich K. Case reports of PML in patients treated for psoriasis. N Engl J Med. 2013;369:1080-1.
 
(31) Kister I, Spelman T, Duquette P, et al. 'Doctor, can I stop my medicine?' Analysis of disease course after stopping disease-modifying therapy in stable MS patients. Neurology. 2015;84:P5. 192.
 
(32) Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis:a randomised study. Lancet. 2001;357:1576-82.
PubMed
(33) Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis(REFLEX):a phase 3 randomised controlled trial. Lancet Neurol. 2012;11:33-41.
 
(34) Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis(TOPIC):a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:977-86.
 
(35) Leist TP, Comi G, Cree BA, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event(ORACLE MS):a phase 3 randomised trial. Lancet Neurol. 2014;13:257-67.
 
P.293 掲載の参考文献
(1) Fogarty E, Schmitz S, Tubridy N, et al. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis:systematic review and network meta-analysis. Mult Scler Relat Disord. 2016;9:23-30.
PubMed
(2) Prosperini L, Sacca F, Cordioli C, et al. Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naive patients with multiple sclerosis. J Neurol. 2016;264:284-94.
PubMed
(3) Kalincik T, Horakova D, Spelman T, et al. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol. 2015;77:425-35.
PubMed
(4) Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis(the REbif vs Glatiramer Acetate in Relapsing MS Disease[REGARD]study):a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7:903-14.
PubMed
(5) O'Connor P, Filippi M, Arnason B, et al. 250μg or 500μg Interferon beta-1b versus 20mg glatiramer acetate in relapsing-remitting multiple sclerosis:a prospective, randomised, multicentre study. Lancet Neurol. 2009;8:889-97.
 
(6) Montalban X, Rio J, Comabella M, et al. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol. 2009;5:553-60.
PubMed
(7) Sormani MP, De Stefano N. Defining and scoring response to IFN-β in multiple sclerosis. Nat Rev Neurol. 2013;9:504-12.
 
(8) Sormani MP, Gasperini C, Romeo M, et al. Assessing response to interferon-β in a multicenter dataset of patients with MS. Neurology. 2016;87:134-40.
 
(9) Perez-Miralles FC, Sastre-Garriga J, Vidal-Jordana A, et al. Predictive value of early brain atrophy on response in patients treated with interferon β. Neurol Neuroimmunol Neuroinflammation. 2015;2:e132.
 
(10) Nakatsuji Y, Okuno T, Moriya M, et al. Elevation of Sema4A implicates Th cell skewing and the efficacy of IFN-β therapy in multiple sclerosis. J Immunol. 2012;188:4858-65.
 
(11) Bermel RA, You X, Foulds P, et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann Neurol. 2013;73:95-103.
PubMed
(12) Rio J, Rovira A, Tintore M, et al. Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis(RRMS)patients. Mult Scler. 2014;20:1602-8.
PubMed
(13) Derfuss T, Ontaneda D, Nicholas J, et al. Relapse rates in patients with multiple sclerosis treated with fingolimod:subgroup analyses of pooled data from three phase 3 trials. Mult Scler Relat Disord. 2016;8:124-30.
PubMed
(14) Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies. Neurology. 2007;69:1391-403.
PubMed
(15) Havrdova E, Galetta S, Stefoski D, et al. Freedom from disease activity in multiple sclerosis. Neurology. 2010;74:3-7.
 
(16) Giovannoni G, Turner B, Gnanapavan S, et al. Is it time to target no evident disease activity(NEDA)in multiple sclerosis? Mult Scler Relat Disord. 2015;4:329-33.
PubMed
(17) Rotstein DL, Healy BC, Malik MT, et al. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72:152-8.
 
(18) Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology. 2002;59:1412-20.
 
(19) Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol. 2014;75:43-9.
 
(20) De Stefano N, Giorgio A, Battaglini M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology. 2010;74:1868-76.
 
(21) Kappos L, De Stefano N, Freedman MS, et al. Inclusion of brain volume loss in a revised measure of "no evidence of disease activity"(NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler. 2016;22:1297-305.
 
(22) Damasceno A, Damasceno BP, Cendes F. No evidence of disease activity in multiple sclerosis:implications on cognition and brain atrophy. Mult Scler. 2016;22:64-72.
PubMed
(23) Cree BAC, Gourraud PA, Oksenberg JR, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016;80:499-510.
PubMed
(24) Bargiela D, Bianchi MT, Westover MB, et al. Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis. Neurolgy. 2017;88:677-84.
 
P.300 掲載の参考文献
(1) Freedman MS, Abdoli M. Evaluating response to disease-modifying therapy in relapsing multiple sclerosis. Expert Rev Neurother. 2015;15:407-23.
PubMed
(2) Rotstein DL, Healy BC, Malik MT, et al. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72:152-8.
 
(3) Cree BA, Gourraud PA, Oksenberg JR, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016;80:499-510.
PubMed
(4) Sormani MP, Gasperini C, Romeo M, et al. Assessing response to interferon-β in a multicenter dataset of patients with MS. Neurology. 2016;87:134-40.
 
(5) Sormani MP, Rio J, Tintore M, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler. 2013;19:605-12.
 
P.307 掲載の参考文献
(1) Atkins HL, Bowman M, Allan D, et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis:a multicenter single-group phase 2 trial. Lancet. 2016;388:576-85.
PubMed
(2) Vollmer T, Panitch H, Bar-Or A, et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler. 2008;14:663-70.
PubMed
(3) Edan G, Comi G, Le Page E, et al. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis:a 3-year randomised trial. J Neurol Neurosurg Psychiatry. 2011;82:1344-50.
 
(4) Dorr J, Paul F. The transition from first-line to second line therapy in multiple sclerosis. Curr Treat Options Neurol. 2015;17:25.
 
(5) Vidal-Jordana A, Tintore M, Tur C, et al. Significant clinical worsening after natalizumab withdrawal:predictive factors. Mult Scler. 2015;21:780-5.
PubMed
(6) Hatcher SE, Waubant E, Nourbakhsh B, et al. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol. 2016;73:790-4.
PubMed
(7) Popescu V, Agosta F, Hulst HE, et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013;84:1082-91.
PubMed
(8) Pareto D, Sastre-Garriga J, Auger C, et al. Juxtacortical lesions and cortical thinning in multiple sclerosis. Am J Neuroradiol. 2015;36:2270-6.
PubMed
P.312 掲載の参考文献
(1) Marrie RA, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Mult Scler. 2015;21:282-93.
 
(2) 小副川 学. MRI画像所見からみた日本人MS病像の解析 2004年MS全国臨床疫学調査. 神経免疫学. 2006;14:151-5.
 
(3) 松井 真, 長山成美. 日本で保険収載されている多発性硬化症疾患修飾薬の使用のしかた. 最新医学. 2016;71:1142-8.
Medical*Online
(4) CQ10-1:膠原病・膠原病関連疾患を合併した多発性硬化症にインターフェロンβ製剤は有効か. In:「多発性硬化症治療ガイドライン」作成委員会, 編. 多発性硬化症治療ガイドライン2010. 東京:医学書院;2010. p.110-6.
 
(5) Caraccio N, Dardano A, Manfredonia F, et al. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy:predictive factors of thyroid disease development and duration. J Clin Endocrinol Metab. 2005;90:4133-7.
PubMed
(6) Noseworthy JH, Bass BH, Vandervoort MK, et al. The prevalence of primary Sjogren's syndrome in a multiple sclerosis population. Ann Neurol. 1989;25:95-8.
 
(7) de Sexe J, Devos D, Castelnovo G, et al. The prevalence of Sjogren syndrome in patients with primary progressive multiple sclerosis. Neurology. 2001;57:1359-63.
 
(8) Annunziata P, De Santi L, Di Rezze S, et al. Clinical features of Sjogren's syndrome in patients with multiple sclerosis. Acta Neuro Scand. 2011;124:109-14.
 
(9) CQ10-2:自己抗体のみ陽性の多発性硬化症にインターフェロンβ製剤は有効か. In:「多発性硬化症治療ガイドライン」作成委員会, 編. 多発性硬化症治療ガイドライン2010. 東京:医学書院;2010. p.117-120.
 
(10) 郡山達男. 多発性硬化症の治療とケア 膠原病合併例の治療. In:辻 省次, 他編. 最新アプローチ多発性硬化症と視神経脊髄炎. 東京:中山書店;2012. p.263-71.
 
(11) Bosch X, Saiz A, Ramos-Casals M, et al. Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol. 2011;7:163-72.
 
P.319 掲載の参考文献
(1) Ghezzi A, Amato MP, Makhani N, et al. Pediatric multiple sclerosis:conventional first-line treatment and general management. Neurology. 2016;87:S97-102.
PubMed
(2) Chitnis T, Tardieu M, Amato MP, et al. International Pediatric MS Study Group Clinical Trials Summit:meeting report. Neurology. 2013;80:1161-8.
 
(3) Chitnis T, Tenembaum S, Banwell B, et al. Consensus statement:evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler. 2012;18:116-27.
PubMed
(4) 鳥巣浩幸. 小児多発性硬化症の治療. MS Frontier. 2015;4:29-31.
 
(5) Yamaguchi Y, Torisu H, Kira R, et al. A nationwide survey of pediatric acquired demyelinating syndromes in Japan. Neurology. 2016;87:2006-15.
PubMed
P.324 掲載の参考文献
(1) Yousry TA, Pelletier D, Cadavid D, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012;72:779-87.
PubMed
(2) Wattjes MP, Richert ND, Killestein J, et al. The chameleon of neuroinflammation:magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler. 2013;19:1826-40.
 
(3) Clifford DB, Nath A, Cinque P, et al. A study of mefloquine treatment for progressive multifocal leukoencephalopathy:results and exploration of predictors of PML outcomes. J Neurovirol. 2013;19:351-8.
 
(4) Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology. 2011;77:1061-7.
PubMed
(5) Giacomini PS, Rozenberg A, Metz I, et al. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med. 2014;370:486-8.
PubMed
P.331 掲載の参考文献
(1) 日本神経治療学会治療指針作成委員会. 標準的神経治療:視神経脊髄炎(NMO). 神経治療学. 2013;30:775-94.
Medical*Online
(2) Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17:1019-32.
PubMed
(3) Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica:review and recommendations. Mult Scler Relat Disord. 2012;1:180-7.
PubMed
(4) Miyamoto K, Kusunoki S. Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial. 2009;13:505-8.
PubMed
(5) Okada K, Tsuji S, Tanaka K. Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Intern Med. 2007;46:1671-2.
PubMed
(6) 抗アクアポリン4抗体陽性視神経炎診療ガイドライン作成委員会. 抗アクアポリン4抗体陽性視神経炎診療ガイドライン. 日眼会誌. 2014;118:446-60.
 
(7) Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica:a retrospective analysis. Mult Scler. 2007;13:968-74.
PubMed
(8) 高井良樹, 中島一郎, 高橋利幸, 他. MS/NMO視神経脊髄炎における経口ステロイド剤の再発予防効果. 日本神経免疫学会 学術集会抄録集22回, 56, 2010.
 
(9) Kojima M, Tanaka T, Izaki S, et al. Tacrolimus suppress the recurrence of patients with Aquaporin-4 antibody positive neuromyelitis optica. ECTRIMS. 2015.
 
P.341 掲載の参考文献
(1) Thone J, Thiel S, Gold R, et al. Treatment of multiple sclerosis during pregnancy-safety considerations. Expert Opin Drug Saf. 2017;16:523-34.
PubMed
(2) Gold R, Phillips JT, Havrdova E, et al. Delayed-release dimethyl fumarate and pregnancy:preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. Neurol Ther. 2015;4:93-104.
PubMed
(3) Kim W, Kim SH, Nakashima I, et al. Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology. 2012;78:1264-7.
PubMed
(4) Shimizu Y, Fujihara K, Ohashi T, et al. Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder. Mult Scler. 2015;22:1413-20.
PubMed
(5) Nour MM, Nakashima I, Coutinho E, et al. Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder. Neurology. 2016;86:79-87.
PubMed
P.346 掲載の参考文献
(1) Saraste M, Vaisanen S, Alanen A, et al. Clinical and immunological evaluation of women with multiple sclerosis during and after pregnancy. Gender Medicine. 2007;4:45-55.
PubMed
(2) Saito S, Nakashima A, Shima T, et al. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol. 2010;63:601-10.
PubMed
(3) Gill M, Ingrid C. The immune system in precnancy:a unique complexity. Am J Reprod Immunol. 2010;63:425-33.
 
(4) Alex T, Martin AL. Multiple sclerosis and pregnancy. Curr Opin Obstet Gynecol. 2011;23:435-9.
 
(5) Christian C, Michael H, Martine MH, et al. Rate of pregnancy-related relapse in, multiple sclerosis. N Engl J Med. 1998;339:285-91.
 
(6) Sandra V, Michael H, Martine H, et al. Pregnancy and multiple sclerosis(the PRIMS study):clinical predictors of post-partum relapse. Brain. 2004;127:1353-60.
 
(7) Vukusic S, Marignier R. Multiple sclerosis and pregnancy in the treatment era. Nat Rev Neurol. 2015;11:280-9.
PubMed
(8) Ferrero S, Pretta S, Ragni N. Multiple sclerosis:management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2004;115:3-9.
PubMed
(9) Keyhanian K, Davoudi V, Etemadifer M, et al. Better prognosis of multiple sclerosis in patients who experienced a full-term pregnancy. Eur Neurol. 2012;68:150-5.
 
(10) Godiguel E, Benesa C, Brassat D, et al. Multiple sclerosis and pregnancy. Revue Neurologique. 2014;170:247-65.
 
(11) Hughes SE, Spelman T, Gray DM, et al. Predictors and dynamics of postpartum relapse in women with multiple sclerosis. Mult Scler. 2014;20:739-46.
 
(12) Portaccio E, Ghezzi A, Hakiki B, et al. Postpartum relapses increase the risk of disability progression in multiple sclerosis:the role of disease modifying drugs. J Neurol Neurosurg Psychiatry. 2013;85:846-51.
 
(13) Hellwig K, Haghikta A, Rockhoff M, et al. Multiple sclerosis and pregnancy:experience from a nation wide database in Germany. Ther Adv Neurol Disord. 2012;5:247-53.
 
(14) Fragos YD, Boggid M, Macias-Isalas MA, et al. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. Clin Neurol Neurosurg. 2013;115:154-9.
 
(15) Hellwig K. Pregnancy in multiple sclerosis. Eur Neurol. 2014;72(supple 1):39-42.
 
(16) Sedighi B, Pardakhty A, Kamali H. Multiple sclerosis and pregnancy;what a neurologist may be asked for? Iran J Neurol. 2014;13:57-63.
 
(17) Coyle PK. Multiple sclerosis in pregnancy. Continuum. 2014;20:42-59.
PubMed
(18) Pozzili C, Pugliatti M. An overview of pregnancy-related issues in patients with multiple sclerosis. Eur J Neurol. 2015;22(Suppl. 2):34-9.
 
(19) Asgarin N, Henriksen TB, Petersen T, et al. Pregnancy outcomes in a woman with neuromyelitis optica. Neurology. 2014;83:1576-7.
 
(20) Huang Y, Wang Y, Zhou Y, et al. Pregnancy in neuromyelitis optica spectrum disorder:a multicenter study from south China. J Neurol Sci. 2017;372:152-6.
 
(21) Shimizu Y, Fujihara K, Ohashi T, et al. Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder. Mult Scler. 2016;22:1413-20.
PubMed
(22) Kim W, Kim SH, Nakashima I, et al. Influence of pregnancy on neuromylitis optica spectrum disorder. Neurology. 2012;76:1264-7.
 
(23) Bourre B, Margnier R, Zeohir H, et al. Neuromyelitis optica and pregnancy. Neurology. 2012;78:875-9.
 
(24) Ringelstein M, Harmel J, Distelmaier F, et al. Neuromyelitis optica and pregnancy therapeutic B cell depletion:infant exposure to anti-AQP4 antibody and low-dose rituximab postpartum. Mult Scler. 2013;19:1544-7.
 
(25) Samira S, Patrick WM, Isabel L, et al. Neuromyelitis optica IgG cases placental inflammation and fetal death. J Immunol. 2013;191:2999-3005.
 
(26) Nour MM, Nakashima I, Coutinho E, et al. Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder. Neurology. 2016;86:79-87.
PubMed
(27) Jonathan RT, Pablo FAG. Plasma exchange therapy for a severe relapse of Devic's disease in a pregnant woman:a case report and concise review. Clin Neurol Neurosurg. 2016;148:86-90.
 
(28) Jurewicz A, Selmaj K. Relapse of neuromyelitis optica during pregnancy-treatment options and literature review. Clin Neurol Neurosurg. 2015;130:159-61.
PubMed
(29) 清水優子. 特集多発性硬化症と視神経脊髄炎 V. 特論 妊娠, 出産時の治療の進め方. 日本臨牀. 2014;72:2053-60.
 
P.354 掲載の参考文献
(1) 日本神経学会・日本神経免疫学会・日本神経治療学会, 監. 「多発性硬化症治療ガイドライン」作成委員会, 編. 多発性硬化症治療ガイドライン2010. 東京:医学書院;2010.
 
(2) 伊藤真也, 村島温子, 編. 薬物治療コンサルテーション 妊娠と授乳. 改訂2版. 東京:南山堂;2014.
 
(3) Hale TW, Rowe HE. Medications & mothers' milk 2017. New York:Springer Publishing Company;2017.
 
(4) LactMed データベース. https://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm
 
(5) Cooper SD, Felkins K, Baker TE, et al. Transfer of methylprednisolone into breast milk in a mother with multiple sclerosis. J Hum Lact. 2015;31:237-9.
 
(6) Strijbos E, Coenradie S, Touw D, et al. High-dose methylprednisolone for multiple sclerosis during lactation:concentrations in breast milk. Mult Scler. 2015;21:797-8.
PubMed
(7) Kim W, Kim SH, Nakashima I, et al. Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology. 2012;78:1264-7.
PubMed

VIII 対症療法

P.362 掲載の参考文献
(1) Shah P. Symptomatic management in multiple sclerosis. Ann Indian Acad Neurol. 2015;18(Suppl 1):S35-42.
 
(2) 大橋高志. 多発性硬化症の治療. 対症療法. 多発性硬化症の治療. 多発性硬化症(MS). II. 免疫性中枢神経疾患. 日本臨床. 2015;73 Suppl 7:228-33.
 
(3) Muto M, Mori M, Sato Y, et al. Current symptomatology in multiple sclerosis and neuromyelitis optica. Eur J Neurol. 2015;22:299-304.
PubMed
(4) 新野正明. MS/NMOの対症療法. 多発性硬化症および類縁疾患の治療の実際. MS Frontier. 2013;11:88-90.
 
(5) Samkoff LM, Goodman AD. Symptomatic management in multiple sclerosis. Neurol Clin. 2011;29:449-63.
PubMed
P.365 掲載の参考文献
(1) Solaro C, Uccelli MM. Management of pain in multiple sclerosis:a pharmacological approach. Nat Rev Neurol 2011;7:519-27.
PubMed
(2) Truini A, Barbanti P, Pozzilli C, et al. A mechanism-based classification of pain in multiple sclerosis. J Neurol. 2013;260:351-67.
PubMed
(3) Khan N, Smith MT. Multiple sclerosis-induced neuropathic pain:pharmacological management and pathophysiological insights from rodent EAE models. Inflammopharmacol. 2014;22:1-22.
PubMed
(4) 岡本智子. 対症療法. In:山村 隆, 編. 多発性硬化症(MS)診療のすべて. 東京:診断と治療社;2012. p.99-108.
 
(5) 日本神経学会・日本神経免疫学会・日本神経治療学会, 監. 多発性硬化症, 視神経脊髄炎診療ガイドライン作成委員会, 編. 多発性硬化症, 視神経脊髄炎治療ガイドライン 2017. 東京:医学書院;2017.
 
(6) Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica:a pilot study. Neurology. 2014;82:1302-6.
PubMed
P.372 掲載の参考文献
(1) Akaishi T, Nakashima I, Misu T, et al. Depressive state and chronic fatigue in multiple sclerosis and neuromyelitis optica. J Neuroimmunol. 2015;283:70-3.
PubMed
(2) Tur C. Fatigue management in multiple sclerosis. Curr Treat Options Neurol. 2016;18:26.
PubMed
(3) Heine M, van de Port I, Rietberg MB, et al. Exercise therapy for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2015:CD009956.
PubMed
(4) Pucci E, Branas P, D'Amico R, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2007:CD002818.
PubMed
(5) Tejani AM, Wasdell M, Spiwak R, et al. Carnitine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2012:CD007280.
PubMed
(6) Rossini PM, Pasqualetti P, Pozzilli C, et al. Fatigue in progressive multiple sclerosis:results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler. 2001;7:354-8.
PubMed
(7) Allart E, Benoit A, Blanchard-Dauphin A, et al. Sustained-released fampridine in multiple sclerosis:effects on gait parameters, arm function, fatigue, and quality of life. J Neurol. 2015;262:1936-45.
PubMed
(8) Ziemssen T, Hoffman J, Apfel R, et al. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis. Health Qual Life Outcomes. 2008;6:67.
PubMed
(9) Metz LM, Patten SB, Archibald CJ, et al. The effect of immunomodulatory treatment on multiple sclerosis fatigue. J Neurol Neurosurg Psychiatry. 2004;75:1045-7.
PubMed
(10) Jongen PJ, Lehnick D, Sanders E, et al. Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate:a prospective, observational, international, multi-centre study. Health Qual Life Outcomes. 2010;8:133.
PubMed
(11) Calkwood J, Cree B, Crayton H, et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis:post hoc analyses of the EPOC trial. BMC Neurol. 2014;14:220.
PubMed
(12) Svenningsson A, Falk E, Celius EG, et al. Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial;a study in the real life setting. PLoS One. 2013;8:e58643.
 
(13) Wilken J, Kane RL, Sullivan CL, et al. Changes in fatigue and cognition in patients with relapsing forms of multiple sclerosis treated with natalizumab:The ENER-G Study. Int J MS Care. 2013;15:120-8.
PubMed
(14) Kunkel A, Fischer M, Faiss J, et al. Impact of natalizumab treatment on fatigue, mood, and aspects of cognition in relapsing-remitting multiple sclerosis. Front Neurol. 2015;6:97.
PubMed
(15) Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry. 1990;147:1493-7.
PubMed
(16) Ehde DM, Kraft GH, Chwastiak L, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry. 2008;30:40-8.
PubMed
(17) Mohr DC, Boudewyn AC, Goodkin DE, et al. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol. 2001;69:942-9.
PubMed
(18) Fiest KM, Walker JR, Bernstein CN, et al. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Mult Scler Relat Disord. 2016;5:12-26.
PubMed
(19) Dalgas U, Stenager E, Sloth M, et al. The effect of exercise on depressive symptoms in multiple sclerosis based on a meta-analysis and critical review of the literature. Eur J Neurol. 2015;22:443-e34.
PubMed
P.377 掲載の参考文献
(1) Davis SL, Wilson TE, White AT, et al. Thermoregulation in multiple sclerosis. J Appl Physiol. 2010;109:1531-7.
PubMed
(2) Opara JA, Brola W, Wylegala AA, et al. Uhthoff's phenomenon 125 years later- what do we know today? J Med Life. 2016;9:101-5.
PubMed
(3) Park K, Tanaka K, Tanaka M. Uhthoff's phenomenon in multiple sclerosis and neuromyelitis optica. Eur Neurol. 2014;72:153-6.
PubMed
(4) Muto M, Mori M, Sato Y, et al. Current symptomatology in multiple sclerosis and neuromyelitis optica. Eur J Neurol. 2015;22:299-304.
PubMed
(5) van Diemen HA, van Dongen MM, Dammers JW, et al. Increased visual impairment after exercise(Uhthoff's phenomenon)in multiple sclerosis:therapeutic possibilities. Eur Neurol. 1992:32:231-4.
PubMed
P.382 掲載の参考文献
(1) 武田景敏. 高次脳機能検査. III. 検査・診断法 特集:多発性硬化症と視神経脊髄炎. 日本臨牀. 2014;72:1989-94.
 
(2) Rao SM, Leo GJ, Ellington L, et al. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology. 1991;41:692-6.
 
(3) Deloire M, Ruet A, Hamel D, et al. Early cognitive impairment in multiple sclerosis predicts disability outcome several years later. Mult Scler. 2010;16:581-7.
PubMed
(4) Zipoli V, Goretti B, Hakiki B, et al. Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes. Mult Scler. 2010;16:62-7.
PubMed
(5) Calabrese M, Agosta F, Rinaldi F, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol. 2009;66:1144-50.
PubMed
(6) Calabrese M, Poretto V, Favaretto A, et al. Cortical lesion load associates with progression of disability in multiple sclerosis. Brain. 2012;135:2952-61.
 
(7) Schoonheim MM, Popescu V, Rueda Lopes FC, et al. Subcortical atrophy and cognition:sex effects in multiple sclerosis. Neurology. 2012;79:1754-61.
PubMed
(8) Reuter F, Zaaraoui W, Crespy L, et al. Cognitive impairment at the onset of multiple sclerosis:relationship to lesion location. Mult Scler. 2011;17:755-8.
PubMed
(9) Rossi F, Giorgio A, Battaglini M, et al. Relevance of brain lesion location to cognition in relapsing multiple sclerosis. PLoS One. 2012;7:e44826.
PubMed
(10) Sepulcre J, Masdeu JC, Pastor MA, et al. Brain pathways of verbal working memory:a lesion-function correlation study. Neuroimage. 2009;47:773-8.
PubMed
(11) Audoin B, Guye M, Reuter F, et al. Structure of WM bundles constituting the working memory system in early multiple sclerosis:a quantitative DTI tractography study. Neuroimage. 2007;36:1324-30.
PubMed
(12) Louapre C, Perlbarg V, Garcia-Lorenzo D, et al. Brain networks disconnection inearly multiple sclerosis cogni-tivedeficits:an anatomo functional study. Hum Brain Mapp. 2014;35:4706-17.
 
(13) van den Heuvel MP, Sporns O. Rich-club organization of the human connectome. J Neurosci. 2011;31:15775-86.
PubMed
(14) Tomassini V, Matthews PM, Thompson AJ, et al. Neuroplasticity and functional recovery in multiple sclerosis. Nat Rev Neurol. 2012;8:635-46.
PubMed
(15) Schoonheim MM, Meijer KA, Geurts JJ. Network collapse and cognitive impairment in multiple sclerosis. Front Neurol. 2015;6:82.
PubMed
(16) Korsholm K, Madsen KH, Frederiksen JL, et al. Recovery from optic neuritis:an ROI-based analysis of LGN and visual cortical areas. Brain. 2007;130:1244-53.
PubMed
(17) Patti F. Treatment of cognitive impairment in patients with multiple sclerosis. Expert Opin Investig Drugs. 2012;21:1679-99.
PubMed
(18) Rosti-Otajarvi EM, Hamalainen PI. Neuropsychological rehabilitation for multiple sclerosis. Cochrane Database Syst Rev. 2014;11:CD009131.
PubMed
(19) Chiaravalloti ND, DeLuca J, Moore NB, et al. Treating learning impairments improves memory performance in multiple sclerosis:a randomized clinical trial. Mult Scler. 2005;11:58-68.
PubMed
(20) Leavitt VM, Wylie GR, Girgis PA, et al. Increased functional connectivity within memory networks following memory rehabilitation in multiple sclerosis. Brain Imaging Behav. 2014;8:394-402.
PubMed
(21) Parisi L, Rocca MA, Valsasina P, et al. Cognitive rehabilitation correlates with the functional connectivity of the anterior cingulate cortex in patients with multiple sclerosis. Brain Imaging Behav. 2014;8:387-93.
PubMed
P.389 掲載の参考文献
(1) Lance JW. Spasticity:disordered motor control. In:Feldman RG, Young RR, Koella WP, eds. Symposium synopsis. Chicago:Year Book Medical Publishers;1980. p.485-94.
 
(2) Sheean G. Pathophysiology of spasticity. In:Sheean G, eds. Spasticity rehabilitation. London:Churchill Communications Europe LTD;1998. p.17-38.
 
(3) O'Dwyer NJ, Ada L. Reflex hyperexcitability and muscle contracture in relation to spastic hypertonia. Curr Opin Neurol. 1996;9:451-5.
PubMed
(4) World Health Organization. International Classification of Functioning Disability and Health(ICF). Geneva:WHO;2001.
 
(5) Amatya B, Khan F, La Martina L, et al. Non pharmacological interventions for multiple sclerosis. Cochrance Database Syst Rev. 2013;(2):CD009974.
 
(6) Ostero-Romero S, Sastre-Garriga J, Comi G, et al. Pharmacological management of spasticity in multiple sclerosis:Systematic review and consensus paper. Mult Scler. 2016;22:1386-96.
 
P.394 掲載の参考文献
(1) Goldstein I, Siroky MB, Sax DS, et al. Neurourologic abnormalities in multiple sclerosis. J Urol. 1982;128:541-5.
PubMed
(2) Hinson JL, Boone TB. Urodynamics and multiple sclerosis. Urol Clin North Am. 1996;23:475-81.
PubMed
(3) Castello T, Girona L, Gomez MR, et al. The possible value of ascorbic acid as a prophylactic agent for urinary tract infection. Spinal Cord. 1996;34:592-3.
PubMed
(4) Jepson RG, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2008;(1):CD001321.
 
P.398 掲載の参考文献
(1) Lew-Starowicz M, Rola R. Prevalence of sexual dysfunctions among women with multiple sclerosis. Sex Disabil. 2013;31:141-53.
PubMed
(2) DasGupta R, Fowler CJ. Sexual and urological dysfunction in multiple sclerosis:better understanding and improved therapies. Curr Opin Neurol. 2002;15:271-8.
PubMed
(3) Previnaire JG, Lecourt G, Soler JM, et al. Sexual disorders in men with multiple sclerosis:evaluation and management. Ann Phys Rehabil Med. 2014;57:329-36.
PubMed
(4) Cordeau D, Courtois F. Sexual disorders in women with MS:assessment and management. Ann Phys Rehabil Med. 2014;57:337-47.
PubMed
(5) Betts CD, Jones SJ, Fowler CG, et al. Erectile dysfunction in multiple sclerosis. Associated neurological and neurophysiological deficits, and treatment of the condition. Brain. 1994;117:1303-10.
PubMed
(6) Mohammadi K, Rahnama P, Mohseni SM, et al. Determinants of sexual dysfunction in women with multiple sclerosis. BMC Neurol. 2013;13:83.
PubMed
(7) Winder K, Linker RA, Seifert F, et al. Neuroanatomic correlates of female sexual dysfunction in multiple sclerosis. Ann Neurol. 2016;80:490-8.
PubMed
(8) Celik DB, Poyraz EC, Bingol A, et al. Sexual dysfunction in multiple sclerosis:gender differences. J Neurol Sci. 2013;324:17-20.
PubMed
(9) Marck CH, Jelinek PL, Weiland TJ, et al. Sexual function in multiple sclerosis and associations with demographic, disease and lifestyle characteristics:an international cross-sectional study. BMC Neurol. 2016;16:210.
PubMed
(10) Merghati-Khoei E, Qaderi K, Amini L, et al. Sexual problems among women with multiple sclerosis. J Neurol Sci. 2013;324:17-20.
 
(11) Fowler CJ, Miller JR, Sharief MK, et al. A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005;76:700-5.
PubMed
(12) Schairer LC, Foley FW, Zemon V, et al. The impact of sexual dysfunction on health-related quality of life in people with multiple sclerosis. Mult Scler. 2014;20:610-6.
PubMed
P.402 掲載の参考文献
(1) Nicholas R, Rashid W. Multiple sclerosis. BMJ Clin Evid. 2012;1-67.
 
(2) Haselkom KJ, Hughes C, Rae-Grant A, et al. Summary of comprehensive systematic review:rehabilitation in multiple sclerosis. Neurology. 2015;85:1896-903.
 
(3) Kjolhede J, Vissing K, Dalgas U. Multiple sclerosis and progressive resistance training:a systematic review. Mult Scler. 2012;18:1215-28.
 
(4) White JL, Dressendorfer HR. Execise and multiple sclerosis. Sports Med. 2004;34:1077-100.
 

IX 説明と医療福祉資源

P.415 掲載の参考文献
(1) 特定疾患の疫学に関する調査研究班. 臨床調査個人票に基づく特定疾患治療研究医療受給者調査報告書;2005.
 
(2) 京極高宣. 障害者の就労支援はどうあるべきか? 職リハネットワーク. 2009;65:5-16.
 
(3) 厚生労働省ホームページ(難病患者の就労支援). http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/koyou_roudou/koyou/shougaishakoyou/06e.html
 
(4) 春名由一郎. 難病のある人の就労支援のために. 千葉:独立行政法人高齢・障害者雇用支援機構障害者職業総合センター(NIVR);2011.
 
P.424 掲載の参考文献
(1) Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis:a consensus approach. Mult Scler. 2008;14:1157-74.
PubMed
(2) Aliaga ES, Barkhof F. MRI mimics of multiple sclerosis. Handb Clin Neurol. 2014;122:291-316.
PubMed
(3) Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med. 2012;366:339-47.
PubMed
(4) Rio J, Rovira A, Tintore M, et al. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler. 2008;14:479-84.
PubMed
(5) Monzani F, Caraccio N, Dardano A, et al. Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med. 2004;3:199-210.
PubMed
P.435 掲載の参考文献
(1) 久保田 馨. 悪い知らせを伝える際のコミュニケーションに関する北米の取り組み(SPIKES)について. In:内富庸介, 藤森麻衣子, 編. がん医療におけるコミュニケーション・スキル. 東京:医学書院;2007. p.23-30.
 
(2) 辻 省次, 総編集. 西澤正豊, 専門編集. すべてがわかる神経難病医療. 東京:中山書店;2015.
 
(3) 横山和正, 富沢雄二, 服部信孝. 多発性硬化症のQoLとケア・生活指導の進め方 免疫性神経疾患. 日本臨牀. 2015;73(増刊7):247-52.
 
(4) 福富崇史. 患者自身が書いた多発性硬化症1年生のためのMS入門書. 名古屋:ブイツーソリューション;2015.
 
(5) 深澤俊行, 編. やさしい多発性硬化症の自己管理-より良い毎日を過ごすためのQ and A-. 東京:医薬ジャーナル社;2014.
 

書評

最近チェックした商品履歴

Loading...